



## NEWS RELEASE

### ORION NUTRACEUTICALS CLOSING OF PRIVATE PLACEMENT

Vancouver, BC, November 30, 2018– **Orion Nutraceuticals Inc.**, (CSE: **ORI**) (the “**Company**” or “**Orion**”) a cannabis life science company, is pleased to announce that it has closed a non-brokered private placement of 1,685,000 common shares at a price of CAD\$0.50 per unit for aggregate gross proceeds of \$842,500. Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share in the capital of the Company for a period of 24 months following the closing of the private placement at a price of CAD\$1.00 per warrant share. The common shares are subject to a four month and one day hold period, from the date of Closing, in accordance with Canadian securities laws.

#### **PRIVATE PLACEMENT – SEPTEMBER 21<sup>ST</sup> CLOSING - CORRECTION**

Orion’s management would like to announce a correction of 80,000 shares to the Treasury Order issued on September 21<sup>st</sup>, 2018. This correction was due to an accounting error and brings the Company’s total shares issued and granted as at September 21, 2018 to 44,761,400.

#### **About Orion Nutraceuticals Inc.**

Orion Nutraceuticals Inc. aims to set a new standard in cannabis life science by producing and developing innovative products with key strategic partners in the industry. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products. Medic-Oasis, Orion’s subsidiary, has submitted its application for an ACMPR license and is currently under review with Health Canada. Build out is expected to begin in Q1 2019, with completion of the 30,000 square foot facility expected by Q3 2019. Orion Nutraceuticals is partners with Colombian based medical cannabis corporation FCM Global. FCM supplies pharmaceutical, nutritional, wellness, and cosmetic companies in legal markets worldwide with customized medical cannabis extracts, oils, and isolates at commercial scale. Orion shares trade in Canada on the CSE under the symbol ORI.

#### **About FCM Global S.A.S.**

FCM Global S.A.S. is a fully licensed Colombian medical cannabis company producing a range of full spectrum oils, CBD isolates, and micro-emulsions in support of finished goods manufacturers in legal markets worldwide. Headquartered in Medellin, with a 235,800 ft<sup>2</sup> production facility in La Ceja, the FCM Global platform encompasses genetics, cultivation, extraction, quality testing, formulation, and distribution. FCM Global's "Co-Sourced Colombia" model reliably delivers lower production costs and high-quality inputs at scale to its clients in the nutritional, wellness, pharmaceutical, and research sectors. FCM Global will soon break ground on FCM Tolima, a planned 450 hectare cultivation and production site which will produce over 1,000 tons of cannabis oil at full capacity. Please see [www.fcm-global.com](http://www.fcm-global.com) for additional information.



ON BEHALF OF THE ORION BOARD

Jonathan Fiteni, CEO  
Orion Nutraceuticals Inc.  
[www.orionnutra.ca](http://www.orionnutra.ca)

Investor Relations  
Robin Linden, Director  
1.604.313.2768  
[investors@orionnutra.ca](mailto:investors@orionnutra.ca)

*This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on [www.sedar.com](http://www.sedar.com).*

*This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.*